1. Search Result
Search Result
Results for "

calmodulin-dependent

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

19

Peptides

6

Natural
Products

18

Recombinant Proteins

18

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15465
    KN-93
    Maximum Cited Publications
    95 Publications Verification

    CaMK Autophagy Cancer
    KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.
    KN-93
  • HY-19805
    STO-609
    30+ Cited Publications

    CaMK AMPK Autophagy Metabolic Disease
    STO-609 is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609
  • HY-N6732
    K-252a
    25+ Cited Publications

    SF2370; Antibiotic K 252a; Antibiotic SF 2370

    Autophagy PKA PKC Trk Receptor CaMK Infection Inflammation/Immunology
    K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca 2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .
    K-252a
  • HY-13290
    KN-62
    10+ Cited Publications

    CaMK P2X Receptor Metabolic Disease Cancer
    KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with a Ki of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II. KN-62 displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM.
    KN-62
  • HY-Z0478
    (-)-Limonene
    1 Publications Verification

    (S)-(-)-Limonene

    Bacterial Antibiotic CaMK Infection Cardiovascular Disease Metabolic Disease
    (-)-Limonene ((S)-(-)-Limonene) is orally active and can cause mild bronchoconstriction. (-)-Limonene alleviates cytosolic and mitochondrial oxidative stress by inhibiting the increase of calcium ions (Ca 2+) and Ca 2+/calmodulin-dependent protein kinase II (CaMKII). It also exerts anti-stress effects by inhibiting the activity of the hypothalamic-pituitary-adrenal (HPA) axis. Additionally, (-)-Limonene can be used as an antibacterial agent in aquaculture .
    (-)-Limonene
  • HY-108599
    DCP-LA
    5+ Cited Publications

    FR236924

    PKC CaMK Phosphatase Apoptosis Neurological Disease
    DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca( 2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .
    DCP-LA
  • HY-100912
    W-7 hydrochloride
    5+ Cited Publications

    Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Potassium Channel Cancer
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .
    W-7 hydrochloride
  • HY-15465B
    KN-93 phosphate
    Maximum Cited Publications
    95 Publications Verification

    CaMK Autophagy Cancer
    KN-93 phosphate is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM .
    KN-93 phosphate
  • HY-P1821
    Myelin Basic Protein
    2 Publications Verification

    MHP4-14

    PKC Neurological Disease
    Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
    Myelin Basic Protein
  • HY-148907

    CaMK MEK Mixed Lineage Kinase RIP kinase Tau Protein Neurological Disease
    CS640 (Compound 19) is a chemical probe and a calmodulin-dependent kinase inhibitor. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, MEK5, RIPK4, mLK3 and PIP5K1, with IC50 values of 8, 3, 1, 1, 25 nM, 5.69, 2.75 and 11.2 μM, respectively. CS640 blocks Aβ-induced hyperphosphorylation of tau protein at the Thr181 site, but fails to protect primary mouse cortical neurons from Aβ-induced toxic damage. CS640 is applicable to research related to Alzheimer's disease .
    CS640
  • HY-P10638

    CaMK Cardiovascular Disease Neurological Disease
    TAT-CN21 is a potent CaMKII inhibitor with an IC50 of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .
    TAT-CN21
  • HY-15465A
    KN-93 hydrochloride
    Maximum Cited Publications
    95 Publications Verification

    CaMK Autophagy Cancer
    KN-93 hydrochloride is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.
    KN-93 hydrochloride
  • HY-115719

    Ser/Thr Kinase Neurological Disease
    NR162 is a selective CASK (Ca 2+/calmodulin-dependent Ser/Thr kinase) inhibitor with an IC50 of 80 nM and a Kd of 22 nM. NR162 shows about 50-fold selectivity for CASK than TYRO3. NR162 targets the unique GFG motif of CASK and has excellent shape complementarity to the CASK ATP binding pocket. NR162 can be used for the research of neurological diseases .
    NR162
  • HY-110140

    CaMK Cardiovascular Disease Neurological Disease
    (E)-KN-93 phosphate is a Ca 2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor with IC50 values of 9 μM and 3 μM against CaMKIIδMonomer and CaMKIIδDodecamer, respectively. (E)-KN-93 phosphate can be used in research on epilepsy, depression, and arrhythmias. .
    (E)-KN-93 phosphate
  • HY-P1247

    Phosphatase Neurological Disease
    Calcineurin autoinhibitory peptide is a selective inhibitor of Ca 2+/calmodulin-dependent protein phosphatase (calcineurin), with an IC50 of ~10 μM. Calcineurin autoinhibitory peptide could protect neurons from excitatory neuronal death .
    Calcineurin autoinhibitory peptide
  • HY-100779

    SMP 114

    CaMK Autophagy Metabolic Disease
    Rimacalib (SMP 114) is a Ca 2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ .
    Rimacalib
  • HY-P0225

    Autocamtide II

    CaMK Autophagy Neurological Disease
    Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.
    Autocamtide 2
  • HY-B1726

    Holocaine

    Phosphodiesterase (PDE) Metabolic Disease
    Phenacaine (Holocaine) is a local agent that can suppress or relieve pain. Phenacaine inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca 2+-ATPase and cyclic nucleotide phosphodiesterases from brain and heart .
    Phenacaine
  • HY-168905

    Calmodulin Cancer
    SGC-CAMKK2-1, a chemical probe, is the selective, inhibitor for calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) with an IC50 of 30 nM. SGC-CAMKK2-1 inhibits AMPK phosphorylation in cell C4-2 with an IC50 of 1.6 μM .
    SGC-CAMKK2-1
  • HY-W013857

    CaMK EGFR Src Cancer
    Lavendustin C is a potent Ca 2+ calmodulin-dependent kinase II (CaMK II) inhibitor with an IC50 of 0.2 µM. Lavendustin C inhibits EGFR-associated tyrosine kinase (IC50=0.012 µM) and pp60 c-src(+) kinase (IC50=0.5 µM) .
    Lavendustin C
  • HY-P1479

    Autophagy CaMK Neurological Disease
    Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
    Calmodulin-Dependent Protein Kinase II (290-309)
  • HY-N1989

    Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB Neurological Disease Cancer
    Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na +/K +-ATPase, Ca 2+-ATPase and Mg 2+-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .
    Bacoside A
  • HY-P3811A

    CaMK Neurological Disease
    Autocamtide-3 acetate, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca 2+/calmodulin-dependent kinase II) (CaMK) substrate .
    Autocamtide-3 acetate
  • HY-146268

    CaMK Neurological Disease
    CaMKIIα-IN-1 (Compound 4d) is an orally active Ca 2+/calmodulin-dependent protein kinase II α (CaMKIIα) inhibitor with a KD of 219 nM for CaMKIIα WT hub. CaMKIIα-IN-1 has good metabolic stability .
    CaMKIIα-IN-1
  • HY-120997

    Berbamine p-nitrobenzoate

    Calmodulin Myosin Phosphodiesterase (PDE) Cardiovascular Disease Cancer
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia .
    E6 Berbamine
  • HY-130368
    W-7
    5+ Cited Publications

    Calmodulin Potassium Channel Phosphodiesterase (PDE) Myosin Apoptosis Cardiovascular Disease
    W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias .
    W-7
  • HY-P1821A
    Myelin basic protein (4-14) TFA
    2 Publications Verification

    MHP4-14 TFA

    PKC Neurological Disease
    Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
    Myelin basic protein (4-14) TFA
  • HY-P1479A

    Autophagy CaMK Neurological Disease
    Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
    Calmodulin-Dependent Protein Kinase II(290-309) acetate
  • HY-P1874

    Calmodulin Neurological Disease
    Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) .
    Calmodulin-Dependent Protein Kinase II (281-309)
  • HY-W170020

    CaMK Metabolic Disease
    PTCA is a potent Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) ligand with a pKi value of 7.2 .
    PTCA
  • HY-P10316

    calmodulin-dependent Protein Kinase I (299-320) Binding Domain

    CaMK Others
    CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca 2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .
    CaMKI(299-320)
  • HY-19805A

    CaMK AMPK Autophagy Metabolic Disease
    STO-609 acetate is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609 acetate
  • HY-19230

    Calmodulin NO Synthase CaMK Calcineurin Proteasome Caspase Cardiovascular Disease
    DY-9760e is a calmodulin (CaM) inhibitor. DY-9760e selectively inhibits the activity of various calmodulin-dependent enzymes by antagonizing the Ca²⁺/CaM complex, exhibiting the strongest inhibitory activity against nNOS, CaM kinase II, and calcineurin (Ki: 0.9, 1.4, and 2.0 μM, respectively). DY-9760e inhibits excessive nitric oxide production and protein tyrosine nitration, as well as the activation of calpain and caspase-3. DY-9760e reduces infarct size, improves cardiac function, and inhibits oxidative stress and cell death. DY-9760e can be used in research on the treatment of myocardial infarction, cerebral ischemia, and other diseases .
    DY-9760e
  • HY-E70950

    Ser/Thr Kinase Neurological Disease
    Calmodulin-dependent protein kinase II, Rat, is a serine-threonine protein kinase involved in neurotransmitter release, stimulation-induced gene expression control, and microtubule-associated protein phosphorylation.
    Calmodulin-dependent Protein Kinase II, Rat
  • HY-P10499

    CaMK Others
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors .
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)
  • HY-137658

    PTP

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CaMK Metabolic Disease
    Purine riboside-5'-O-triphosphate, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC50 values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate also inhibits calmodulin-dependent protein kinase II (CaMKII) with a Ki value of 590 µM .
    Purine riboside triphosphate
  • HY-P5525

    Autocamtide-3 Derived Inhibitory Peptide

    CaMK Others
    AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)
    AC3-I, myristoylated
  • HY-P3944

    CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent Protein Kinase Substrate
  • HY-P3943

    CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate Analog is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent Protein Kinase Substrate Analog
  • HY-P1247A

    Phosphatase Neurological Disease
    Calcineurin autoinhibitory peptide TFA is a selective inhibitor of Ca 2+/calmodulin-dependent protein phosphatase (calcineurin), with an IC50 of ~10 μM. Calcineurin autoinhibitory peptide TFA could protect neurons from excitatory neuronal death .
    Calcineurin autoinhibitory peptide TFA
  • HY-P3811

    CaMK Neurological Disease
    Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca 2+/calmodulin-dependent kinase II) (CaMK) substrate .
    Autocamtide-3
  • HY-130748

    PKC Phosphodiesterase (PDE) Infection
    K-252d is an indolocarbazole alkaloid found in Nocardiopsis. It is a PKC inhibitor that inhibits PKC isolated from rat brain (IC50=350 nM). It also inhibits calcium- and calmodulin-dependent phosphodiesterase isolated from bovine heart (IC50=46.2 μM).
    K-252d
  • HY-137658A

    PTP tetrasodium

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CaMK Metabolic Disease
    Purine riboside-5'-O-triphosphate sodium, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC50 values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate sodium inhibits calmodulin-dependent protein kinase II (CaMKII) with a Ki value of 590 µM .
    Purine riboside-5'-O-triphosphate sodium
  • HY-111093

    CaMK Neurological Disease
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .
    Protein kinase inhibitor 8
  • HY-108599R

    FR236924 (Standard)

    Reference Standards PKC CaMK Phosphatase Apoptosis Neurological Disease
    DCP-LA (Standard) is the analytical standard of DCP-LA. This product is intended for research and analytical applications. DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis[1][2][3].
    DCP-LA (Standard)
  • HY-156104

    PROTACs CaMK Neurological Disease
    CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .
    CaMKIIα-PHOTAC
  • HY-P1716

    PKC Neurological Disease
    Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .
    Neuropeptide DF2
  • HY-P2209

    Daechuine S27; N-Demethylamphibine H

    Parasite Phosphodiesterase (PDE) Infection
    Nummularine B (Daechuine S27; N-Demethylamphibine H) is an anti-parasite agent. Nummularine B inhibits calmodulin-dependent phosphodiesterase activity with an IC50 of 16.8 μM. Nummularine B inhibits the growth of Plasmodium and Leishmania donovani in vitro. Nummularine B inhibits the calmodulin-dependent activity of actomyosin Ca 2+-ATPase. Nummularine B is applicable to research related to malaria and visceral leishmaniasis .
    Nummularine B
  • HY-P10367

    MAPKAPK2 (MK2) Checkpoint Kinase (Chk) AMPK Others
    Ziptide is a substrate for MAPK activated protein kinase 2 (MAPKAPK2, Km = 5 μM), MAPKAPK3 (Km = 30 μM), PARK (Km = 40 μM), checkpoint kinase 1 (Chk1, Km = 5 μM), AMP-activated protein kinase (AMPK, Km = 75 μM), and calcium/calmodulin-dependent protein kinase II (CamKII, Km = 300 μM) .
    Ziptide
  • HY-114554

    Phosphodiesterase (PDE) PKC Bacterial Infection
    KS 619-1 is a Ca 2+/calmodulin-dependent cyclic nucleotide phosphodiesterase inhibitor. KS 619-1 exhibits strong inhibitory activity against this enzyme derived from bovine brain and heart, but shows weak inhibitory effects on calmodulin-independent phosphodiesterase and protein kinase C. KS 619-1 displays weak antibacterial activity against Staphylococcus aureus .
    KS 619-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: